A Pfizer result is unsettling the gene therapy push for Duchenne muscular dystrophy: The boys didn't improve even though a ...

Pfizer has told 75 employees in Sanford, North Carolina, that their positions have been eliminated. | Pfizer has told 75 ...

Last week, the company started rolling submissions for a biologics license application (BLA) for deramiocel as a treatment for DMD cardiomyopathy with the US Food and Drug Adminis ...

SAVANNAH, Ga. -- Delandistrogene moxeparvovec (Elevidys), a gene therapy approved to treat Duchenne muscular dystrophy, ...

Capricor Therapeutics is taking a victory lap for their phase 2 Duchenne muscular dystrophy (DMD) trial. | Capricor ...

Oropharyngeal cancer is a type of head and neck cancer that tends to affect people between 50 and 80 but is becoming more ...

We recently published a list of 10 Biggest Stocks with Negative Beta to Consider. In this article, we are going to take a ...

Since the FDA cleared Sarepta Thereapeutics' gene therapy for nearly all people with Duchenne, its stock price has tanked.

Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

Outcomes of interest in this study were time from diagnosis to initial prescription fill for an oral multiple myeloma (MM) ...

trial for its Duchenne muscular dystrophy (DMD) cell therapy, deramiocel. Last week, the company started rolling submissions for a biologics license application (BLA) for deramiocel as a treatment ...